Document is current
Any future updates will be listed below
-
Authors
Abegesah, Aburough
Oh, Do-Youn
Lim, KyoungSoo
Fan, Chunling
Chen, Cecil
Kim, Chong
Wang, Julie
Xynos, Ioannis
Zotkiewicz, Magdalena
Ren, Song
Phipps, Alex
Gibbs, Megan
Zhou, Diansong
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 11 December 2024
First Online: 17 January 2025
Declarations
:
: AA, KL, CF, JW, IX, MZ, SR, MG, and DZ are current employees of and shareholders in AstraZeneca.CC, CK and AP are former employees of AstraZeneca. DYO is a consultant and on the advisory board for: AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD, LG Chem, Astellas, Abbvie, J-Pharma, Mirati Therapeutics, Eutilex, Moderna, and Idience. DYO has also received research grants from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok.
: This study was approved by the institutional review board/ethics committee of each institution participating TOPAZ-1. Written informed consent was obtained from patients (or their legal guardian) to participate in the study.
